Clavulanate Potassium with Silicon Dioxide (Syloid)
A blended powder mixture of Clavulanate potassium and silicon dioxide
Weight Ratio 1:1

The product is suitable for the manufacture of powder for deferral following the accumulation of proper Excipients and Amoxicillin.

Therapeutic category:
 A beta- lactamase inhibitor that augments the activity of amoxicillin as a wide-ranging antibiotic

Pharmacopoeia Quality:
The Clavulanate potassium conforms to the
- Ph.Eur.
- BP
latest editions

White to off-white crystalline powder

Content (HPLC):
K-Clavulanate: 46.1 - 52.8%
(clavulanic acid): (38.7 - 44. 3%)

Water (Karl Fischer): < 1.5 %

Tapped bulk density (U SP): > 0.25 g/ml

Shelf life:
3 years in the original packaging beneath 'storage conditions

Storage conditions:
 Less than 15 °C, protected from light and moisture

See segment "Packaging"

Regulatory Information:
See segment "Regulatory Information"
The information contained herein is believed to be accurate but all recommendations are made without warranty and nothing be construed to imply any guarantee.
Pharma categories patient's education business prospect feedback